(53 days)
No
The description focuses on a traditional automated susceptibility testing method based on microdilution and growth monitoring, with no mention of AI or ML algorithms for analysis or interpretation.
No.
This device is described as a "laboratory aid in the determination of in vitro susceptibility to antimicrobial agents," which means it assists in diagnostic testing, not in direct treatment or therapy.
Yes
The device aids in determining the in vitro susceptibility of microorganisms to antimicrobial agents, which is a diagnostic function to guide treatment. It provides an MIC value and interpretive category result, which are crucial for diagnosing antibiotic resistance and informing clinical decisions.
No
The device description clearly details physical components like "VITEK 2 AST Cards" and the "VITEK 2 System" or "VITEK 2 Compact" which are hardware instruments used to process the cards and monitor growth. This is not a software-only device.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states it is "designed for antimicrobial susceptibility testing of Gram positive microorganisms" and is intended for use "as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents." The term "in vitro" is a key indicator of an IVD.
- Device Description: The description details how the device tests bacterial isolates in a laboratory setting using a miniaturized microdilution technique. This process is performed outside of the human body.
- Performance Studies: The performance studies compare the device's performance to a "CLSI broth microdilution reference method," which is a standard laboratory technique for in vitro testing.
- Predicate Device: The predicate device listed (VITEK 2 Gram Positive Daptomycin) is also an IVD, indicating the regulatory pathway for this type of device.
- Intended User/Care Setting: The intended user is a "laboratory aid," further reinforcing its use in a clinical laboratory setting for in vitro testing.
All of these factors align with the definition and characteristics of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
VITEK® 2 Gram Positive Tigecycline is designed for antimicrobial susceptibility testing of Gram positive microorganisms and is intended for use with the VITEK 2 and VITEK 2 Compact Systems as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents. VITEK 2 Gram Positive Tigecycline is a qualitative test. Tigecycline has been shown to be active against the organisms listed below according to the FDA label for the antimicrobial.
Active in vitro and in clinical infections:
Enterococcus faecalis (Vancomycin-susceptible isolates only) Staphylococcus aureus (methicillin-susceptible and -resistant isolates) Streptococcus agalactiae
Active in vitro but their clinical significance is unknown: Enterococcus faecium (Vancomycin susceptible and resistant isolates) Staphylococcus epidermidis Staphylococcus haemolyticus Enterococcus casseliflavus.
The VITEK® 2 Antimicrobial Susceptibility Test (AST) is intended to be used with the VITEK® 2 and VITEK® 2 Compact Systems for the automated quantitative or qualitative susceptibility testing of isolated colonies for the most clinically significant aerobic gram-negative bacilli, Staphylococcus spp., Enterococcus spp., Streptococcus agalactiae, and S. pneumoniae.
Product codes
LON
Device Description
The antimicrobial presented in VITEK 2 AST Cards is in concentrations equivalent by efficacy to standard method concentrations in mcg/ml. The VITEK 2 AST Cards are essentially miniaturized versions of the doubling dilution technique for determining the minimum inhibitory concentration (MIC) microdilution methodology.
The bacterial isolate to be tested is diluted to a standardized concentration in 0.45% saline before being used to rehydrate the antimicrobial medium within the card. The VITEK 2 System automatically fills, seals and places the card into the incubator/reader. The VITEK 2 Compact has a manual filling and sealing operation. The VITEK 2 monitors the growth of each well in the card over a defined period of time (up to 18 hours). At the completion of the incubation cycle, a report is generated that contains the MC value along with the interpretive category result for each antibiotic contained on the card.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
laboratory aid
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
An external evaluation was conducted with fresh and stock clinical isolates and stock challenge strains. The external evaluations were designed to confirm the acceptability of VITEK 2 Gram Positive Tigecycline by comparing its performance with the CLSI broth microdilution reference method. The data is representative of performance on both the VITEK 2 and VITEK 2 Compact instrument platforms, as evidenced in the AST equivalency study presented in the VITEK 2 Compact 510(k), K050002.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
VITEK® 2 Gram Positive Tigecycline demonstrated substantially equivalent performance when compared with the CLSI broth microdilution reference method, as defined in the FDA Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA, Issued Feb. 5, 2003.*
The Premarket Notification (510[k]) presents data in support of VITEK 2 Gram Positive Tigecycline. An external evaluation was conducted with fresh and stock clinical isolates and stock challenge strains. The external evaluations were designed to confirm the acceptability of VITEK 2 Gram Positive Tigecycline by comparing its performance with the CLSI broth microdilution reference method. The data is representative of performance on both the VITEK 2 and VITEK 2 Compact instrument platforms, as evidenced in the AST equivalency study presented in the VITEK 2 Compact 510(k), K050002. VITEK 2 Gram Positive Tigecycline demonstrated acceptable performance of 99.4% overall Category Agreement. Reproducibility and Quality Control demonstrated acceptable results.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
99.4% overall Category Agreement.
Predicate Device(s)
Reference Device(s)
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 866.1645 Fully automated short-term incubation cycle antimicrobial susceptibility system.
(a)
Identification. A fully automated short-term incubation cycle antimicrobial susceptibility system is a device that incorporates concentrations of antimicrobial agents into a system for the purpose of determining in vitro susceptibility of bacterial pathogens isolated from clinical specimens. Test results obtained from short-term (less than 16 hours) incubation are used to determine the antimicrobial agent of choice to treat bacterial diseases.(b)
Classification. Class II (special controls). The special control for this device is FDA's guidance document entitled “Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA.”
0
Image /page/0/Picture/0 description: The image shows the logo for bioMerieux on the left side of the image. To the right of the logo is the number K072695. The logo consists of a circle with lines inside of it and the name of the company below it. The number is handwritten and appears to be a serial number.
510(k) SUMMARY
VITEK® 2 Gram Positive Tigecycline
N 1 6 2007
510(k) Submission Information:
Submitter's Name: | bioMérieux, Inc. |
---|---|
Address: | 595 Anglum Road |
Hazelwood, MO 63042 | |
Contact Person: | Jolyn Tenllado |
Senior Regulatory Affairs Specialist | |
Phone Number: | 314-731-8386 |
Fax Number: | 314-731-8689 |
Date of Preparation: | September 20, 2007 |
B. Device Name: | |
Formal/Trade Name: | VITEK® 2 Gram Positive Tigecycline ( $≤$ 0.12 - $≥$ 2 µg/ml) |
Classification Name: | Fully Automated Short-Term Incubation Cycle |
Antimicrobial Susceptibility Device, 21 CFR 866.1645 | |
Common Name: | VITEK 2 AST-GP Tigecycline |
C. Predicate Device: | VITEK 2 Gram Positive Daptomycin (K050075). |
D. 510(k) Summary:
B. D
VITEK® 2 Gram Positive Tigecycline is designed for antimicrobial susceptibility testing of Gram positive microorganisms and is intended for use with the VITEK 2 and VITEK 2 Compact Systems as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents. VITEK 2 Gram Positive Tigecycline is a qualitative test. Tigecycline has been shown to be active against the organisms listed below according to the FDA label for the antimicrobial.
Active in vitro and in clinical infections: Enterococcus faecalis (Vancomycin-susceptible isolates only) Staphylococcus aureus (methicillin-susceptible and -resistant isolates) Streptococcus agalactiae
Active in vitro but their clinical significance is unknown: Enterococcus faecium (Vancomycin susceptible and resistant isolates) Staphylococcus epidermidis Staphylococcus haemolyticus Enterococcus casseliflavus.
The antimicrobial presented in VITEK 2 AST Cards is in concentrations equivalent by efficacy to standard method concentrations in mcg/ml. The VITEK 2 AST Cards are essentially miniaturized
bioMérieux, Inc.
595 Anglum Road, Hazelwood, Missouri 63042-2320, USA Phone: 314/731-8500 800/638-4835 Fax: 314/731-8700
1
versions of the doubling dilution technique for determining the minimum inhibitory concentration (MIC) microdilution methodology.
The bacterial isolate to be tested is diluted to a standardized concentration in 0.45% saline before being used to rehydrate the antimicrobial medium within the card. The VITEK 2 System automatically fills, seals and places the card into the incubator/reader. The VITEK 2 Compact has a manual filling and sealing operation. The VITEK 2 monitors the growth of each well in the card over a defined period of time (up to 18 hours). At the completion of the incubation cycle, a report is generated that contains the MC value along with the interpretive category result for each antibiotic contained on the card.
VITEK 2 Gram Positive Tigecycline demonstrated substantially equivalent performance when compared with the CLSI broth microdilution reference method, as defined in the FDA Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA, Issued Feb. 5, 2003.*
The Premarket Notification (510[k]) presents data in support of VITEK 2 Gram Positive Tigecycline. An external evaluation was conducted with fresh and stock clinical isolates and stock challenge strains. The external evaluations were designed to confirm the acceptability of VITEK 2 Gram Positive Tigecycline by comparing its performance with the CLSI broth microdilution reference method. The data is representative of performance on both the VITEK 2 and VITEK 2 Compact instrument platforms, as evidenced in the AST equivalency study presented in the VITEK 2 Compact 510(k), K050002. VITEK 2 Gram Positive Tigecycline demonstrated acceptable performance of 99.4% overall Category Agreement. Reproducibility and Quality Control demonstrated acceptable results.
*Note: This device clinical trial was initiated prior to the March 5, 2007 issuance of the revised guidance, which is why the older quidance document is cited.
2
DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Image /page/2/Picture/2 description: The image shows the seal of the U.S. Department of Health & Human Services. The seal features a stylized eagle with three lines representing its wings. The eagle is facing right. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES (USA)" is arranged in a circular pattern around the eagle.
NOV 1 6 2007
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Ms. Jolyn Tellando Senior Regulatory Affairs Specialist bioMérieux, Inc. 595 Anglum Road Hazelwood, MO 63042
Re: K072695
Trade/Device Name: VITEK® 2 Gram Positive Tigecycline (≤ 0.12 -> 2 µg/ml) Regulation Number: 21 CFR 866.1645 Regulation Name: Short term Antimicrobial Susceptibility Test Regulatory Class: Class II Product Code: LON Dated: September 20, 2007 Received: September 24, 2007
Dear Ms. Tellando:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
3
Page 2 –
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at 240-276-0450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Sally attaym
Sally A. Hojvat, M.Sc., Ph.D. Director Division of Microbiology Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
4
Indications for Use
510(k) Number (if known): K072695
Device Name: VITEK® 2 Gram Positive Tigecycline ( 2 µg/ml)
Indications For Use:
VITEK® 2 Gram Positive Tigecycline is designed for antimicrobial susceptibility testing of Gram positive microorganisms and is intended for use with the VITEK 2 and VITEK 2 Compact Systems as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents. VITEK 2 Gram Positive Tigecycline is a qualitative test. Tigecycline has been shown to be active against the organisms listed below according to the FDA label for the antimicrobial.
Active in vitro and in clinical infections:
Enterococcus faecalis (Vancomycin-susceptible isolates only) Staphylococcus aureus (methicillin-susceptible and -resistant isolates) Streptococcus agalactiae
Active in vitro but their clinical significance is unknown: Enterococcus faecium (Vancomycin susceptible and resistant isolates) Staphylococcus epidermidis Staphylococcus haemolyticus Enterococcus casseliflavus.
The VITEK® 2 Antimicrobial Susceptibility Test (AST) is intended to be used with the VITEK® 2 and VITEK® 2 Compact Systems for the automated quantitative or qualitative susceptibility testing of isolated colonies for the most clinically significant aerobic gramnegative bacilli, Staphylococcus spp., Enterococcus spp., Streptococcus agalactiae, and S. pneumoniae.
Prescription Use (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concerrence of CORH, Office of In Vitro Diagnostic Devices (OIVD) Fleddle est
Division Sign-Off
Office of In Vitro Diagnostic Device Evaluation and Safety
Page 1 of 1
510(k) K072695
K072695, Amended p. 9